Type IV Hypersensitivity Reaction Summary

Overview of Type IV Hypersensitivity Reaction

Type IV hypersensitivity reactions, also known as delayed hypersensitivity reactions, are T-cell mediated immune responses that typically develop between 48 to 72 hours after antigen exposure, though they can take weeks to manifest. These reactions involve CD4+ and CD8+ T cells, leading to cytokine release, inflammation, and tissue damage.

Clinical Implications

These reactions are crucial for combating certain intracellular pathogens and may result in conditions like contact dermatitis, transplant rejection, and drug-related skin injuries. Diagnosis involves patient history, patch testing, biopsies, and laboratory studies. Treatments include removing triggers and using corticosteroids and immunosuppressants based on severity.

Key Pathophysiology

Delayed hypersensitivity reactions rely on activated T cells that respond to previously encountered antigens leading to inflammation. The pathophysiology is further classified into Type IVa (Th1 mediated), Type IVb (Th2 mediated), Type IVc (cytotoxic T cell mediated), and Type IVd (neutrophilic inflammation).

Epidemiology

Approximately 20% of individuals have contact allergies, with nickel being a prevalent allergen. Severe conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis affect 1.4 to 12.7 individuals per million annually.

Treatment and Management

Management includes avoiding triggers, applying topical corticosteroids, and systemically addressing severe cases with immunosuppressants and supportive care. Preventive education on allergen avoidance is also emphasized.

Prognosis

While the prognosis for most acute conditions is favorable, conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis present a higher risk of mortality. Sarcoidosis generally has a good prognosis with appropriate management.